Last reviewed · How we verify
Libexin®
Libexin is a non-narcotic antitussive agent that suppresses cough by acting as a local anesthetic on the respiratory mucosa and reducing airway irritation.
Libexin is a non-narcotic antitussive agent that suppresses cough by acting as a local anesthetic on the respiratory mucosa and reducing airway irritation. Used for Dry cough and unproductive cough in various respiratory conditions.
At a glance
| Generic name | Libexin® |
|---|---|
| Also known as | prenoxdiazine |
| Sponsor | Dompé Farmaceutici S.p.A |
| Drug class | Non-narcotic antitussive |
| Modality | Small molecule |
| Therapeutic area | Respiratory / Pulmonology |
| Phase | Phase 3 |
Mechanism of action
Libexin (prenoxdiazine) works through a combination of local anesthetic effects on the airways and central cough suppression without opioid activity. It reduces the sensitivity of cough receptors in the respiratory tract, thereby decreasing the cough reflex while maintaining normal airway clearance and respiratory function.
Approved indications
- Dry cough and unproductive cough in various respiratory conditions
Common side effects
- Drowsiness
- Dizziness
- Gastrointestinal upset
- Headache
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Libexin® CI brief — competitive landscape report
- Libexin® updates RSS · CI watch RSS
- Dompé Farmaceutici S.p.A portfolio CI